Brugada syndrome (BrS) is a heritable disease that results in sudden cardiac death. In the exome/genomic era, certain reported pathogenic variants in some genetic diseases have been reclassified as benign owing to their high frequency in some ancestries. In the present study, we comprehensively reassessed all previously reported pathogenic variants of BrS. We collected all pathogenic variants of BrS reported in the Human Gene Mutation Database and ClinVar throughout April 2017. We compared the minor allele frequency (MAF) of each variant among different ancestries by searching public whole-genome and exome databases. After considering the maximum credible allele frequency, variants with a MAF ≥ 0.001 were considered to be of questionable pathogenicity. We also investigated the percentage of SCN5A variants with a MAF ≥ 0.001 in 124 BrS patients from the Han Chinese population. We collected a total of 440 BrS variants, of which 18 had a MAF ≥ 0.001. There was a greater percentage of non-SCN5A variants with a MAF ≥ 0.001 than of SCN5A variants (21.8 versus 1.6%, < 0.0001). There were fewer frameshift and nonsense mutations than missense mutations (0.9 versus 5.6%, = 0.032). Of the 18 variants, 14 (77.8%) were present only in the reference Asian population. In our cohort, we identified two SCN5A variants (p.A226V and p.V1340I) with MAFs ≥ 0.001 (0.45%). In conclusion, ancestral differences are important when considering the pathogenicity of BrS variants, especially in the case of missense variants and non- variants, which may be pathogenic in some ancestries but only disease-predisposing in others.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328444PMC
http://dx.doi.org/10.3389/fgene.2018.00680DOI Listing

Publication Analysis

Top Keywords

≥ 0001
20
pathogenic variants
16
variants maf
16
maf ≥
16
variants
14
reported pathogenic
12
scn5a variants
12
ancestral differences
8
brugada syndrome
8
variants brs
8

Similar Publications

Purpose: Monocyte chemoattractant protein-1 (MCP-1/CCL2) plays a key role for infiltration of monocytes/macrophages and studies have demonstrated that the MCP-1/C-C chemokine receptor 2 (CCR2) axis might be involved in the pathogenesis and progression of abdominal aortic aneurysms (AAA). Molecular imaging has shown potential for human clinical research studies. We evaluated the expression of CCR2 in patients with small AAA using single-photon emission computed tomography (SPECT) with the technetium-99m-6-hydrazinylnicotinoyl-C-C-chemokine receptor-2 ligand (Tc-HYNIC-CCR2-L).

View Article and Find Full Text PDF

Background And Aims: An arterial aneurysm is characterized by a localized expansion of a blood vessel relative to its original dimensions. Specifically, an abdominal aortic aneurysm (AAA) is identified as an aortic diameter measuring at least one and a half times the standard diameter at the renal artery level, approximately equivalent to 2.0 cm.

View Article and Find Full Text PDF

Improving quantification accuracy of a nuclear Overhauser enhancement signal at -1.6 ppm at 4.7 T using a machine learning approach.

Phys Med Biol

January 2025

Vanderbilt University Medical Center, 1161 21st Ave. S, Medical Center North, AAA-3112, Nashville, Tennessee, 37232-2102, UNITED STATES.

Objective: A new nuclear Overhauser enhancement (NOE)-mediated saturation transfer MRI signal at -1.6 ppm, potentially from choline phospholipids and termed NOE(-1.6), has been reported in biological tissues at high magnetic fields.

View Article and Find Full Text PDF

Thus far, no manufacturing process able to support industrialization has been reported for the recombinant human brain-derived neurotrophic factor (rhBDNF). Here, we described the setup of a new protocol for its production in () and its purification to homogeneity. A synthetic gene, codifying for the neurotrophin precursor, was inserted into an expression vector and transformed into BL21 (DE3) strain.

View Article and Find Full Text PDF

Background: Adalimumab, an anti-TNF-α biologic agent, has emerged as a principal treatment option for patients with non-infectious uveitis. The influence of adalimumab anti-drug antibodies (AAA) on the efficacy of adalimumab therapy is not yet fully understood. We aim to understand their clinical implications in the context of therapeutic drug monitoring and the factors contributing to the formation of these antibodies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!